President Donald Trump has announced plans for significant tariffs on pharmaceutical imports, aiming to boost domestic drug manufacturing and reduce reliance on foreign sources, particularly China and India. While Trump highlighted the U.S.’s inability to produce sufficient antibiotics as a national security risk, experts warn these tariffs could exacerbate drug shortages—especially for generics, which make up 90% of prescriptions—and drive up medication costs. Critics argue the move risks harming patient welfare, undermining U.S. credibility, and pushing allies closer to China, with any increase in domestic production likely years away
Discover how we can elevate your portfolio and deliver exceptional growth. NEW Monthly Payout Of At Least 0.5% In US Dollars
AlgoTrader 